| P/E (FY) | — | Sales (TTM) | $4.25B |
| Earnings (TTM) | $1.29B | ROE | 20.15% |
| Net Margin | 30.41% | ROIC | 26.92% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 112.09% |
| Market Cap | $53.85B | Trading Days | 2515 |
| 52W High | 833.60 |
| 52W Low | 508.60 |
| % Off High | −7.39% |
| YTD | 7.70% | 1Y | 50.84% |
| 3Y | 70.04% | 5Y | 200.86% |
| 10Y | 5907.78% | Since incept. (ann.) | 50.91% |
| Ann. Volatility (1Y) | 34.05% | Ann. Volatility (3Y) | 37.86% |
| Sharpe (1Y) | 1.39 | Sharpe (3Y) | 0.66 |
| Max Drawdown (1Y) | −27.37% | Max Drawdown (3Y) | −39.25% |
| Beta (3Y, vs SPY) | 0.24 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| EW | Edwards Lifesciences Corp | $49.38B | 46.9 |
| 207940.KS | Samsung Biologics Ltd | $49.32B | 101.8 |
| 7741.T | HOYA CORPORATION | $48.97B | 31.8 |
| BDX | BECTON DICKINSON & CO | $46.40B | 28.9 |
| IDXX | IDEXX LABORATORIES INC /DE | $44.95B | 43.6 |
| REGN | REGENERON PHARMACEUTICALS, INC. | $65.34B | 16.8 |
| BSX | BOSTON SCIENTIFIC CORP | $68.43B | 23.7 |
| IQV | IQVIA HOLDINGS INC. | $41.32B | 31.6 |
| AGL | agilon health, inc. | $41.04B | — |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $40.45B | 28.7 |
| 4519.T | CHUGAI PHARMACEUTICAL CO., LTD. | $71.80B | 26.5 |
| A | AGILENT TECHNOLOGIES, INC. |
| $39.63B |
| 30.7 |
